BN Business News
添加企业 →
本文翻译正在准备中。在此之前,我们暂时显示英文原文。

监管与法律 · 1997/12/91 分钟阅读

Prospective Grant of Exclusive License: Therapeutic Uses of Blood Vessel Growth Promoting Peptides Including Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF) for Cardiovascular Disease and Conditions Such as Myocardial Ischemia

本地自动翻译 · 来源原始语言

摘要

This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a domestic exclusive license to practice the inventions embodied in the patent referred to below to Collateral Therapeutics of San Diego, California. The patent rights in these inventions have been assigned to the government of the United States of America. The patent to be licensed is: ``Method To Foster Myocardial Blood Vessel Growth And Improve Blood Flow To The Heart'', U.S. Patent Application Serial No. 07/799,830 filed November 27, 1991, which issued as U.S. Patent No. 5,244,460 on September 14, 1993.

来源原始语言: Federal Register — All Documents打开原始公告 →

探索专题

商业洞察 →